Qualitative Analysis of Primary Care Provider Prescribing Decisions for Urinary Tract Infections.

antibiotic stewardship antibiotics fluoroquinolones guidelines urinary tract infections

Journal

Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404

Informations de publication

Date de publication:
19 Jun 2019
Historique:
received: 14 05 2019
revised: 13 06 2019
accepted: 14 06 2019
entrez: 29 6 2019
pubmed: 30 6 2019
medline: 30 6 2019
Statut: epublish

Résumé

Inappropriate choices and durations of therapy for urinary tract infections (UTI) are a common and widespread problem. In this qualitative study, we sought to understand why primary care providers (PCPs) choose certain antibiotics or durations of treatment and the sources of information they rely upon to guide antibiotic-prescribing decisions. We conducted semi-structured interviews with 18 PCPs in two family medicine clinics focused on antibiotic-prescribing decisions for UTIs. Our interview guide focused on awareness and familiarity with guidelines (knowledge), acceptance and outcome expectancy (attitudes), and external barriers. We followed a six-phase approach to thematic analysis, finding that many PCPs believe that fluoroquinolones achieve more a rapid and effective control of UTI symptoms than trimethoprim-sulfamethoxazole or nitrofurantoin. Most providers were unfamiliar with fosfomycin as a possible first-line agent for the treatment of acute cystitis. PCPs may be misled by advanced patient age, diabetes, and recurrent UTIs to make inappropriate choices for the treatment of acute cystitis. For support in clinical decision making, few providers relied on guidelines, preferring instead to have decision support embedded in the electronic medical record. Knowing the PCPs' knowledge gaps and preferred sources of information will guide the development of a primary care-specific antibiotic stewardship intervention for acute cystitis.

Identifiants

pubmed: 31248119
pii: antibiotics8020084
doi: 10.3390/antibiotics8020084
pmc: PMC6627108
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Zambon Pharmaceuticals
ID : WBS 2180536501

Références

JAMA. 1999 Oct 20;282(15):1458-65
pubmed: 10535437
Clin Infect Dis. 1999 Oct;29(4):745-58
pubmed: 10589881
Lancet. 1992 Jul 11;340(8811):127
pubmed: 1352007
Diabetes Care. 2008 Jul;31(7):1380-5
pubmed: 18362200
Clin Infect Dis. 2009 Aug 1;49(3):402-8
pubmed: 19545207
Arch Pediatr Adolesc Med. 2009 Nov;163(11):978-85
pubmed: 19884587
Clin Infect Dis. 2011 Mar 1;52(5):e103-20
pubmed: 21292654
Cardiology. 2011;120(2):103-10
pubmed: 22156660
Am J Med. 2012 Dec;125(12):1228.e23-1228.e28
pubmed: 23026288
Scand J Prim Health Care. 2013 Mar;31(1):50-5
pubmed: 23281925
Drug Saf. 2013 Sep;36(9):709-21
pubmed: 23888427
Clin Infect Dis. 2013 Oct;57(7):971-80
pubmed: 23948133
Ann Epidemiol. 2014 Apr;24(4):279-85
pubmed: 24472364
PLoS One. 2014 Feb 03;9(2):e87899
pubmed: 24498394
JAMA. 2014 Feb 26;311(8):844-54
pubmed: 24570248
Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5694-9
pubmed: 24706808
Neurology. 2014 Sep 30;83(14):1261-3
pubmed: 25150290
JAMA. 2014 Oct 22-29;312(16):1677-84
pubmed: 25335150
Emerg Infect Dis. 2014 Dec;20(12):2041-7
pubmed: 25418868
Infect Control Hosp Epidemiol. 2015 Feb;36(2):142-52
pubmed: 25632996
J Infect Dis. 2015 Dec 15;212(12):1853-5
pubmed: 25969562
Open Forum Infect Dis. 2015 Oct 26;2(4):ofv159
pubmed: 26753168
JAMA. 2016 Feb 9;315(6):562-70
pubmed: 26864410
JAMA. 2016 May 3;315(17):1864-73
pubmed: 27139059
J Antimicrob Chemother. 2016 Dec;71(12):3562-3567
pubmed: 27494927
Open Forum Infect Dis. 2016 Aug 02;3(3):ofw159
pubmed: 27704014
Birth Defects Res A Clin Mol Teratol. 2016 Nov;106(11):940-949
pubmed: 27891788
Diabetes Res Clin Pract. 2017 Jul;129:197-202
pubmed: 28544925
Br J Clin Pharmacol. 2017 Nov;83(11):2557-2571
pubmed: 28722171
Qual Quant. 2018;52(4):1893-1907
pubmed: 29937585
J Urol. 2018 Dec;200(6):1174-1191
pubmed: 29940246
Antimicrob Agents Chemother. 2018 Jul 27;62(8):
pubmed: 29967028
Int Urogynecol J. 2019 Jul;30(7):1187-1194
pubmed: 30099566
Open Forum Infect Dis. 2018 Aug 10;5(9):ofy198
pubmed: 30191156
Open Forum Infect Dis. 2018 Nov 16;5(11):ofy297
pubmed: 30539040
Fam Med. 1998 Feb;30(2):117-21
pubmed: 9494802

Auteurs

Larissa Grigoryan (L)

Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX 77098, USA. grigorya@bcm.edu.

Susan Nash (S)

Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX 77098, USA. sgnash@bcm.edu.

Roger Zoorob (R)

Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX 77098, USA. Roger.Zoorob@bcm.edu.

George J Germanos (GJ)

Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX 77098, USA. George.Germanos@bcm.edu.

Matthew S Horsfield (MS)

Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX 77098, USA. Matthew.Horsfield@bcm.edu.

Fareed M Khan (FM)

Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX 77098, USA. fkhan@bcm.edu.

Lindsey Martin (L)

Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA. Lindsey.Martin@bcm.edu.
Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA. Lindsey.Martin@bcm.edu.

Barbara W Trautner (BW)

Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA. trautner@bcm.edu.
Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA. trautner@bcm.edu.

Classifications MeSH